Work

A phase III trial-in-progress comparing tislelizumab plus chemotherapy with placebo plus chemotherapy as first-line therapy in patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma.

Year: 2019

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2019.37.15_suppl.tps2655

Authors: Rui-hua Xu, Hendrik-Tobias Arkenau, Yung-Jue Bang, Crystal S. Denlinger, Ken Kato, Josep Tabernero, Jin Wang, Jiang Li, Henry Castro, Markus Hermann Moehler

Institutions: Sun Yat-sen University Cancer Center, Sarah Cannon Research Institute, Seoul National University, Fox Chase Cancer Center, National Cancer Center Hospital, Vall d'Hebron Institute of Oncology, BeiGene (China), Johannes Gutenberg University Mainz

Language: English

Topic: Gastric Cancer Management and Outcomes

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2946839779

Cites:

Cited by: 1

Related to: 10